A new tech revolution promises to reverse aging. Reality
A new tech revolution promises to reverse aging, but consumer biohacking is racing ahead of hard proof. ABC's Four Corners finds most clinic therapies lack human evidence, while early biotech trials—autophagy drugs, thymus work, and epigenetic reprogramming—are only beginning. Proven longevity still rests on diet, exercise, and social connection.
Key Takeaways
- Most biohacking clinic offerings lack rigorous human evidence, according to ABC's Four Corners investigation.
- Well-funded startups are testing autophagy boosters, immune rejuvenation, and partial epigenetic reprogramming in early human trials.
- Experts say NAD+ boosters and many IV wellness treatments remain unproven in randomized trials.
- Senolytic fisetin is popular among some researchers, but human data are still limited.
- Exercise, healthy diet, and social ties remain the strongest evidence-backed path to a longer healthspan.
What did the new aging investigation actually find?
ABC News reporter Norman Swan and the Four Corners team tracked the boom from New York biohacking conferences to Silicon Valley labs and Australian telehealth clinics. The ABC investigation shows longevity businesses cashing in while very few consumer therapies are backed by human evidence.
Billionaire-backed startups carry eye-watering valuations despite having no product to sell. That gap between hype and proof is why coverage in the longevity and biohacking space keeps returning to the same question: what works today?
Which anti-aging technologies show real scientific promise?
Geroscience treats cancer, heart disease, dementia, and vision loss as diseases of aging. If one therapy hits shared causes, investor Karl Pfleger notes, it could mitigate multiple age-related diseases at once.
Retro Biosciences, launched with $US180 million from OpenAI's Sam Altman and valued at $US1.8 billion, is running a first-in-human safety trial in Adelaide of a drug aimed at restoring cellular recycling, or autophagy. Intervene Immune is exploring thymus regeneration after a small trial showed MRI evidence of recovery, though researchers warn of cancer and autoimmune risks.
Life Biosciences, co-founded by Harvard geneticist David Sinclair, is testing partial epigenetic reprogramming in humans for the first time—starting in the eye for glaucoma and optic-nerve damage because the enclosed space may be safer.
Separately, New York Post reporting on fisetin—a plant flavonoid sold as a senolytic that clears "zombie" senescent cells—notes mouse studies extending healthspan and lifespan. Human studies remain limited, even as some longevity researchers reportedly take the compound themselves.
What can you do now that actually works?
University of Sydney aging authority Professor Luigi Fontana says the tricks are already known: good food, physical exercise, and calorie restriction with optimal nutrition. Endocrinologist Professor Katherine Samaras calls NAD boosters "a complete waste of money," arguing mitochondrial function improves with eating less and drinking less alcohol.
Fontana adds there are interesting animal data for some supplements, but he has not seen randomized clinical trials proving disease improvement or even solid safety data in humans. In 2026, lifestyle still offers the strongest evidence for cutting chronic-disease risk and extending healthy years.